文献速递老年慢病共病管理多重用药

美国国家衰老研究所研讨会:老药或膳食补充剂作为衰老细胞清除剂或衰老细胞表型调节剂用于临床试验的考量

National Institute on Aging Workshop: Repurposing Drugs or Dietary Supplements for Their Senolytic or Senomorphic Effects: Considerations for Clinical Trials.
PubMed 文献 · J Gerontol A Biol Sci Med Sci · 2021-01-01

美国国家衰老研究所于2019年8月召开研讨会,学术界、产业界和政府科学家共同审视了将潜在可再利用药物或膳食补充剂用于II期临床试验的相关问题,以评估其衰老细胞清除或衰老细胞表型调节作用在治疗或预防年龄相关疾病中的获益与风险。与会者指出需考虑候选药物对多种衰老结局的潜在影响、药物对衰老细胞杀伤的特异性及衰老细胞清除与细胞毒性效应之间的平衡,并强调老年人共病和多重用药的潜在相互作用。

要点

  • 候选药物需评估对多种衰老结局的潜在影响及衰老细胞清除与细胞毒性效应的平衡。
  • 需要特异性衰老细胞类型标志物来评估干预反应。
  • 老年人共病及其治疗可能与候选药物存在潜在相互作用。

核心结论

  • 考虑候选药物对多种衰老结局的潜在影响很重要。
  • 评估药物杀伤衰老细胞的特异性及衰老细胞清除与细胞毒性效应之间的平衡很重要。
  • 需要特定衰老细胞类型的标志物来评估干预反应。
  • 老年人共存疾病及其治疗可能存在潜在相互作用。
  • 标准化测量可增强数据比较与合并。

研究设计与样本

  • 美国国家衰老研究所于2019年8月召开研讨会,学术界、产业界和政府科学家参与。
  • 会议审视了潜在可再利用药物或膳食补充剂进行II期临床试验的相关问题。
  • 迄今仅开展了小规模初步试验。

主要发现

  • 与会者回顾了细胞衰老、几类衰老细胞清除剂和衰老细胞表型调节剂的机制与效应及其在治疗或预防疾病中的潜在作用。
  • 与会者回顾了衰老相关分泌表型调节剂、衰老标志物需求、数据与标本资源、试验规划基础设施。
  • 与会者回顾了候选药物对老年多重疾病和多重用药患者结局的潜在影响。

关键数值与推荐

  • 迄今仅开展了小规模初步试验。

临床怎么用

  • 在老年人中评估候选药物时需考虑共存疾病及其治疗的潜在相互作用。
  • 使用标准化测量以增强数据比较与合并。
  • 采用特定衰老细胞类型标志物评估干预反应。

局限性

  • 迄今仅开展了小规模初步试验。
  • 需要进一步表征人类细胞衰老表型以开发更好、更特异的衰老细胞清除剂和衰老细胞表型调节剂。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cell senescence is implicated in numerous age-related conditions. Drugs and nutritional supplements developed for a variety of purposes kill senescent cells (senolytics) or suppress their secretions (senomorphics). There is interest in repurposing such drugs to treat or prevent age-related diseases. To date, only small-scale preliminary trials have been conducted. METHOD: At a workshop convened by the National Institute on Aging in August 2019, academic, industry, and government scientists reviewed issues for phase II trials of potentially repurposable drugs, or dietary supplements, to assess benefits and risks of their senolytic (killing senescent cells) or senomorphic (altering senescent cells' phenotypes) effects in treating or preventing age-related conditions. RESULTS: Participants reviewed mechanisms and effects of cellular senescence, senolytics, and senomorphics of several classes and their potential role in treating or preventing disease, modulators of the senescence-associated secretory phenotype, needs for senescence markers, data and specimen resources, infrastructure for planning trials, and potential effects on outcomes in older patients with multimorbidity and polypharmacy. CONCLUSIONS: Participants noted the importance of considering potential effects of candidate drugs on multiple aging outcomes. It is important to assess drugs' specificity for killing senescent cells and the balance between senolytic and cytotoxic effects. Markers of specific senescent cell types are needed to assess intervention responses. There are potential interactions with coexisting diseases and their treatments in older persons. Standardized measures could enhance comparisons and pooling of data. Additional characterization of human cell senescent phenotypes is needed for developing better and more specific senolytics and senomorphics.

来源:J Gerontol A Biol Sci Med Sci,查看原文。版权归原作者所有。

引用

  1. Romashkan S, Chang H, Hadley EC, et al. National Institute on Aging Workshop: Repurposing Drugs or Dietary Supplements for Their Senolytic or Senomorphic Effects: Considerations for Clinical Trials. J Gerontol A Biol Sci Med Sci. 2021. PMID: 33528569. doi:10.1093/gerona/glab028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。